ArchiMed and management have sold EUROLyser to Antech Diagnostics, a subsidiary of Mars Veterinary Health
EUROLyser, headquartered in Salzburg, Austria, is a leading diagnostics company focusing on the development and design of point-of-care testing (POCT) equipment and kits for the veterinary and human healthcare markets. EUROLyser’s patented technology and the usage of high-standard reagents in closed systems enables customers to obtain high quality test results. The products, including analyzers, proprietary test kits and reagents, are sold through a global distribution network in Europe, North America and the Asia-Pacific region.
Since its inception in 2005, EUROLyser has become a global leading player in the POCT business with strongly growing revenues. After the acquisition of a majority stake by ArchiMed in 2019, EUROLyser received strategic and operational support to further drive the strong development and pursue an ambitious growth as well as expansion strategy. ArchiMed’s strong experience in the industry and the implemented strategic measures resulted in a great performance of EUROLyser, increasing the profit more than two-fold, boosting average annual sales growth to more than 25% during its holding period and raising the interest of other market participants.
Lincoln International managed a structured off-market mergers and acquisitions (M&A) process, using its market expertise to handle the process with only a limited number of parties. A well-adapted process design and vis-á-vis communications paired with strong execution capacities resulted in a fast-track due diligence process with the favored bidder and the completion of the transaction. Involving offices in the United States, Switzerland and Germany, the process is an example of Lincoln International’s joint capabilities in the healthcare sector.
ArchiMed is a leading investment firm with offices in the U.S. and Europe that is focused exclusively on the healthcare industry. Prioritizing the areas of biopharmaceutical products and services, life science tools, medical devices and technologies, diagnostics, health technology and consumer health, ArchiMed’s operational mix of medical, scientific and financial expertise allows to serve as both a strategic and financial partner to the businesses. This expertise helps partners to innovate and expand their products and enables the internationalization of services. Since inception, ArchiMed has been a committed impact investor, both directly and through its Eurêka Foundation.
Lincoln International served as a trusted partner to the shareholders at each stage of the process, providing invaluable insights based on deep industry knowledge, intimate buyer relationships and strong process expertise and complemented this with a high-quality, hardworking team at all levels.
Meet our Senior Team
I enjoy working closely with clients to overcome challenging situations and to develop strategies to meet their business goals.
Managing Director | Management Board MemberFrankfurt
View More Transactions in Healthcare
Lincoln International advised Medisolv on receiving a strategic investment from BVP Forge
Lincoln International advised Millbrook Healthcare Group on the sale of Ross Care to Medequip, a subsidiary of Medux
Lincoln International advised Standard Investment on the sale of Dierenartsen Groep Nederland to VetPartners, a portfolio company of BC Partners
Lincoln International advised Syst'am, a portfolio company of Meanings Capital Partners, on the acquisition of Järven Health Care
Lincoln International advised Alaris Equity Partners, in partnership with Brookfield Special Investments, on raising $546 million in equity and $180 million in debt for Sono Bello
Lincoln International advised kiana group in its sale to Kalaidos, a subsidiary of Klett Group
Lincoln International advised Grant Avenue Capital in its launch with Helios Clinical Research
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.